The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma
The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma
复制标题
DOI：
10.1016/j.intimp.2017.02.027
复制
发表时间：
2017-05-01
影响因子：
5.6
通讯作者：
Hu, Likuan
中科院分区：
文献类型：
--
作者：
Cong, Lihong;Hu, Likuan
目的：HALP对食管癌的预测价值目前尚不清楚。方法：收集2010年1月1日至2014年12月31日在齐鲁医院接受铂类药物治疗的男性食管鳞状细胞癌（ESCC）患者的临床资料，分析HALP对ESCC疗效的预测价值。治疗方案为确定性放化疗，包括多西他赛加顺铂或卡铂。确定性放化疗的反应评估是基于计算机断层扫描（CT）和钡餐检查结果。HALP的中位数为48.34。低HALP值组患者的放化疗有效率为35%，高HALP值组患者的放化疗有效率为78.95%（P = 0.010）。此外，2个患者组的中位无进展生存期存在显著差异（10.7 vs. 24.7 m，P = 0.041）。在多变量分析中，HALP高于4834的患者的无进展生存期长于HALP ≤ 4834的患者（HR 2.745; 95% CI，1.176-6.408; P = 0.020）。然而，高HALP组和低HALP组之间的总生存期无显著差异。结论：我们的数据表明，预处理HALP可以预测铂类为基础的放化疗的肿瘤反应和无进展生存期的男性食管鳞癌患者。因此，HALP可用于指导食管鳞癌患者的个体化治疗策略。(C)2017爱思唯尔B. V.保留所有权利。
Objective: The predictive value of HALP in esophageal cancer is currently unclear. We aimed to evaluate the value of HALP in predicting platinum-based definitive chemoradiotherapy response in male patients with esophageal squamous cell carcinoma.Methods: Data from all newly diagnosed patients with esophageal squamous cell carcinoma (ESCC) were collected from January 1, 2010 to December 31, 2014 in Qilu Hospital. The treatment protocol was definitive chemoradiotherapy consisting of docetaxel plus cisplatin or carboplatin. The response assessment of the definitive chemoradiotherapy was based on computed tomography (CT) and barium meal test results.Results: A total of 39 patients were included in the present study. The median value of HALP was 48.34. The chemoradiotherapy response rate of patients in the low HALP value group was 35%, compared with 78.95% of patients in the high HALP group (P = 0.010). Additionally, the median progression-free survival in the 2 patient groups was significantly different (10.7 vs. 24.7 m, P = 0.041). In the multivariate analysis, patients with HALP higher than 4834 had longer progression-free survival than patients with HALP of 4834 or less (HR 2.745; 95% Cl, 1.176-6.408; P = 0.020). However, there was no significant difference for overall survival between the high HALP group and low HALP group.Conclusion: Our data suggested that pretreatment HALP could predict the platinum-based chemoradiotherapy response of tumors and progression free survival in male patients with ESCC. Therefore, HALP could be used in routine clinical practice to guide the therapeutic strategies for individual treatment in patients with ESCC. (C) 2017 Elsevier B.V. All rights reserved.